KureCells UF-Kure19 granted RMAT designation by FDA based on promising efficacy for LBCL and follicular lymphoma and rapid manufacturing rkjamvi@gmail.com October 17, 2025 KureCells Share share .face-icon{fill:#fff;} .tw-icon{fill:#fff;} .ln-icon{fill:#fff;} .pn-icon{fill:#fff;}
KureCells Kure Cells closed pre-Series A funding round led by Waed Ventures (Aramco) alongside NantBio, US93 and Qomel rkjamvi@gmail.com October 23, 2025
https://marity.qodeinteractive.com/wp-content/uploads/2022/11/Josh-Woodward-Gravity-1.mp3 KureCells NCI $2.2 M Grant to support Phase 2 UF-Kure19 trial rkjamvi@gmail.com August 8, 2025
Leave a Reply